Abstract

Obesity-driven type 2 diabetes (T2D) remains a major global health challenge. Activation or recruitment of 
thermogenic adipocytes  classical brown adipose tissue (BAT) and inducible beige adipocytes within white 
adipose tissue (WAT) increases energy expenditure, improves glucose handling and lipid metabolism, and thus 
represents a promising therapeutic axis for obesity and T2D. Nanomedicine offers tools to (1) deliver 
thermogenic drugs selectively to adipose depots, (2) protect and sustain release of labile agents (peptides, nucleic 
acids), (3) enable cell- and organ-targeting via surface ligands, and (4) combine diagnostics with therapy 
(theranostics). This review synthesizes current understanding of brown and beige adipose biology, surveys 
nanotechnology-based strategies for adipose targeting and thermogenic activation (including small-molecule, 
peptide, oligonucleotide, and biomaterial approaches), summarizes preclinical and early translational evidence, 
and discusses major challenges (targeting specificity, biodistribution, safety, and manufacturability) and future 
directions. We argue that rationally designed nanocarriers—especially lipid-based systems, polymeric particles, 
and targeted ligand conjugates—can overcome pharmacokinetic and safety limitations of systemic thermogenic 
agents and accelerate clinical translation of adipose-directed therapies for obesity-driven diabetes.  
Keywords: brown adipose tissue, beige fat, nanomedicine, thermogenesis, obesity-driven diabetes